Imagine your body's security system is turned off so a new organ doesn't get rejected. This leaves a door open for a dormant virus called CMV to wake up and cause serious damage. This project identifies specific biological 'red flags' to predict which patients will get sick and how severe it will be, allowing doctors to act before the virus takes over.
Immunosuppressive drugs used in organ transplants make patients highly vulnerable to CMV infections, which cause significant morbidity and mortality. There is currently no precise way to predict which patients will develop severe disease versus those who will control the virus.
A longitudinal cohort of 463 SOT recipients and two predictive biological signatures (one for infection risk and one for disease severity).
If you are a diagnostics company dealing with the lack of early warning tools for post-transplant infections — this project developed predictive signatures that identify the risk of CMV infection early after transplantation. This allows for the creation of targeted screening kits to improve patient outcomes.
If you are a biotech firm dealing with the challenge of balancing graft rejection and infection risk — this project developed methods to increase CMV-specific immunity using immunomodulatory molecules. This provides a path toward drugs that stop the virus without triggering organ rejection.
If you are a clinic operator dealing with high morbidity and mortality rates from CMV — this project developed a personalized clinical prevention strategy based on a cohort of 450 patients. This reduces the cost and risk associated with treating severe, late-stage CMV disease.
Based on available project data, no pricing or cost information for the signatures has been provided.
The project uses a European network of 25 partners and a cohort of 450 patients to validate signatures, suggesting a scalable model for clinical adoption across multiple countries.
Based on available project data, specific IP or licensing agreements are not mentioned.
The project runs from 2022-11-01 to 2027-10-31, with a 'proof-of-concept' study planned for prospective validation.
The project aims to provide signatures at day 0 of infection and early after transplantation to enable personalized clinical prevention and treatment.
The consortium is heavily research-driven, consisting of 10 universities and 9 research institutes, with a low industry presence (1 company, 4% ratio). While the academic weight is strong across 8 countries, the lack of industrial partners suggests the project is currently focused on discovery and validation rather than immediate commercial productization.
Contact Universite de Bordeaux regarding the HORUS cohort results
Contact us to identify licensing opportunities for the CMV predictive signatures.
